TESARO, Myriad Announce Companion Diagnostics Collaboration - Quick Facts

(RTTNews) - TESARO, Inc. (TSRO) and Myriad Genetics (MYGN) announced a collaboration utilizing Myriad's myChoice HRD companion diagnostic or CDx to identify tumor tissue with a deficiency in homologous recombination.

Under the agreement, TESARO will utilize Myriad's test to enrich the target population for potential responders to niraparib. Myriad will provide testing services and pursue necessary regulatory approvals in support of TESARO's development of niraparib.

The companies also described new data demonstrating that Myriad's myChoice HRD score is predictive of niraparib sensitivity in patient-derived xenograft models of ovarian cancer.

These results were presented today by Dr. Paul Haluska, Jr., Associate Professor of Oncology at the Mayo Clinic, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.